Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06835114

Reconstruction of Diffusely Diseased Left Anterior Descending with Left Internal Mammary Artery On-lay Patch or Saphenous Vein Patch Without Endarterectomy by Opening the Whole Wall of the Diseased Segment(s) Has Less Risk and Fewer Complications Compared to Endarterectomy Technique

The objective of this study is to compare different surgical strategies for management of severely diseased LAD artery during CABG i.e. LIMA on-lay patch vs. saphenous vein patch and the distal in situ LIMA and saphenous vein graft (LIMA+ SVG).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

Total myocardial revascularization is the primary aim of coronary artery bypass grafting (CABG) . Conventional CABG does not attain sufficient myocardial revascularization in severely diseased left anterior descending coronary artery (LAD). Coronary endarterectomy for severely atherosclerotic LAD was first introduced by Bailey and his coworkers , but it has a higher risk of morality and poor outcomes. The reconstruction of LAD with saphenous vein or left internal mammary artery (LIMA) combined with endarterectomy was described by Fundaro and others surgeons for better long-term patency of LIMA graft and to avoid the drawbacks of endarterectomy. Reconstruction of diffusely diseased LAD with LIMA on-lay patch or saphenous vein patch without endarterectomy by opening the whole wall of the diseased segment(s) has less risk and fewer complications compared to endarterectomy technique. However, the superiority of LIMA path versus saphenous vein patch is still controversial.

In addition, the LIMA patch is occasionally not available as a bypass to LAD, for example with relatively shorter LIMA due to enlarged left ventricle, difficulty in harvesting the proximal LIMA, accidental injury of the LIMA pedicle during harvesting, calcification of the middle or distal LIMA or mismatching between the LAD and distal LIMA. To overcome this, an end-to-end anastomosis with the distal in situ LIMA and saphenous vein graft (SVG) was performed to establish a composite graft to bypass the LAD.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • included patients with long-segment diffusely diseased LAD, with good ejection fraction and elective surgery.

Exclusion criteria

  • Patients with associated valve surgery, left ventricular EF less than 40%, and severe comorbidities (renal or liver failure), preoperative dialysis, and hemodynamic instability, emergency operations were excluded.

Treatment and study plan

CABG

Procedure

CABG

LIMA on lay patch

Procedure

Left internal mammary artery harvesting with on lay patch on left anterior descending coronary artery

Safenous vein patch

Procedure

Safenous vein patch on left anterior descending artery

Primary outcomes

  1. Serum troponin level

    Time frame: From enrollment to 1 month after intervention

    Measure serum troponin level after 48h , after 1 week and after 1 month

Study contacts

Contact information is provided by the study sponsor or research team.

Ahmed Ibrahim Gadallah

CONTACT

[email protected]

+201067172284

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Official study title

Different Surgical Strategies for Management of Severely Diseased Left Anterior Descending Artery During Coronary Artery Bypasses Grafting

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Feb 19, 2025
Registry last updated
Feb 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.